These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group. Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab. Afifi S; Michael A; Lesokhin A Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916 [TBL] [Abstract][Full Text] [Related]
9. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison. Usmani SZ; Diels J; Ito T; Mehra M; Khan I; Lam A Am J Hematol; 2017 Aug; 92(8):E146-E152. PubMed ID: 28474745 [TBL] [Abstract][Full Text] [Related]
10. Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. Chehab S; Panjic EH; Gleason C; Lonial S; Nooka AK Future Oncol; 2018 Dec; 14(30):3111-3121. PubMed ID: 30136602 [TBL] [Abstract][Full Text] [Related]
11. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. Moreau P; van de Donk NW; San Miguel J; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos MV Drugs; 2016 May; 76(8):853-67. PubMed ID: 27113582 [TBL] [Abstract][Full Text] [Related]
12. Daratumumab: monoclonal antibody therapy to treat multiple myeloma. Xia C; Ribeiro M; Scott S; Lonial S Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963 [TBL] [Abstract][Full Text] [Related]
13. Daratumumab for the treatment of multiple myeloma. Touzeau C; Moreau P Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255 [TBL] [Abstract][Full Text] [Related]
14. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma. Salomon-Perzyński A; Walter-Croneck A; Usnarska-Zubkiewicz L; Dytfeld D; Zielińska P; Wojciechowska M; Hołojda J; Robak P; Pasternak A; Knopińska-Posłuszny W; Hawrylecka D; Wójtowicz M; Szeremet A; Osowiecki M; Mordak-Domagała M; Zaucha JM; Giannopoulos K; Warzocha K; Jamroziak K Adv Med Sci; 2019 Sep; 64(2):349-355. PubMed ID: 31125864 [TBL] [Abstract][Full Text] [Related]
16. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. Richard S; Jagannath S; Cho HJ; Parekh S; Madduri D; Richter J; Chari A Expert Rev Hematol; 2021 Jan; 14(1):31-45. PubMed ID: 33331794 [No Abstract] [Full Text] [Related]
17. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future. Sherbenou DW; Mark TM; Forsberg P Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795 [TBL] [Abstract][Full Text] [Related]
18. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma. Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113 [TBL] [Abstract][Full Text] [Related]
19. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359 [TBL] [Abstract][Full Text] [Related]
20. Emerging antibodies for the treatment of multiple myeloma. Zagouri F; Terpos E; Kastritis E; Dimopoulos MA Expert Opin Emerg Drugs; 2016 Jun; 21(2):225-37. PubMed ID: 27195659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]